Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer. A randomized clinical trial.
Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL et al, for the CANVAS Investigators.
JAMA 2023; 329: 1924-1933.
This study included 671 patients with cancer and a new episode of VTE. After six months, the risk of recurrent VTE was not inferior with oral anticoagulation (6.1per cent), compared to those receiving low molecular weight heparin (8.8 per cent). Bleeding complication rates were similar.
Comment: Reassuring, and easier for patients.
29 August 2023
Read paperAcademy
Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
